Evidence map›Paper›PMID 38713388›Full record

ArticleAnnals of surgical oncology2024

Oncologic Safety of Immediate Oncoplastic Surgery Compared with Standard Breast-Conserving Surgery for Patients with Invasive Lobular Carcinoma.

Israel Falade, Kayla Switalla, Astrid Quirarte, Molly Baxter, Daniel Soroudi, Harriet Rothschild, Shoko Emily Abe, Karen Goodwin, Merisa Piper, Jasmine Wong and 2 more

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of surgical oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Observational
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Israel FaladeSchool of Medicine, University of California-San Francisco, San Francisco, CA, USA. israel.falade@ucsf.edu.ORCID http://orcid.org/0009-0001-8624-385X
Kayla SwitallaUniversity of Minnesota Medical School, Minneapolis, MN, USA.
Astrid QuirarteDivision of Surgical Oncology, Department of Surgery, University of California-San Francisco, San Francisco, CA, USA.
Molly BaxterDivision of Surgical Oncology, Department of Surgery, University of California-San Francisco, San Francisco, CA, USA.
Daniel SoroudiSchool of Medicine, University of California-San Francisco, San Francisco, CA, USA.
Harriet RothschildSchool of Medicine, University of California-San Francisco, San Francisco, CA, USA.
Shoko Emily AbeDivision of Surgical Oncology, Department of Surgery, University of California-San Francisco, San Francisco, CA, USA.
Karen GoodwinDivision of Surgical Oncology, Department of Surgery, University of California-San Francisco, San Francisco, CA, USA.
Merisa PiperDivision of Plastic and Reconstructive Surgery, Department of Surgery, University of California-San Francisco, San Francisco, CA, USA.
Jasmine WongDivision of Surgical Oncology, Department of Surgery, University of California-San Francisco, San Francisco, CA, USA.
Robert FosterDivision of Plastic and Reconstructive Surgery, Department of Surgery, University of California-San Francisco, San Francisco, CA, USA.
Rita A MukhtarDivision of Surgical Oncology, Department of Surgery, University of California-San Francisco, San Francisco, CA, USA.

Funding

Identifying responders to chemotherapy in invasive lobular carcinoma of the breast: development of a multivariable clinical prediction toolK08CA256047 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MUKHTAR, RITA · 2021 to 2025
$1.3M
Division of Cancer Prevention, National Cancer Institute K08CA256047NCI NIH HHS K08 CA256047
6 · The paper itself

Abstract

backgroundInvasive lobular carcinoma (ILC) of the breast grows in a diffuse pattern, resulting in a high risk of positive margins at surgical resection. Oncoplastic approaches have been shown to reduce this risk, but concerns persist around the safety of immediate oncoplastic surgery for those with ILC. This study evaluated the short- and long-term oncologic outcomes of immediate oncoplastic surgery for patients with ILC.

methodsThis study retrospectively analyzed an institutional database of stages I to III ILC patients who underwent breast-conserving surgery (BCS) with or without immediate oncoplastic surgery (oncoplastic closure or oncoplastic reduction mammoplasty [ORM]). The study compared positive margin rates, rates of successful BCS, and recurrence-free survival (RFS) by type of surgery.

resultsFor 494 patients the findings showed that the use of immediate ORM was associated with significantly lower odds of positive margins (odds ratio [OR], 0.34; 95 % confidence interval [CI], 0.17-0.66; p = 0.002). Both lumpectomy with oncoplastic closure and ORM were significantly associated with higher rates of successful BCS than standard lumpectomy (94.2 %, 87.8 %, and 73.9 %, respectively; p < 0.001). No difference in RFS was observed between those undergoing immediate oncoplastic surgery and those undergoing standard lumpectomy alone.

conclusionsThe patients with stages I to III ILC who underwent immediate oncoplastic surgery had significant benefits including lower odds of positive margins and higher rates of successful BCS, with both types of immediate oncoplastic surgery showing similar RFS compared with lumpectomy alone. This supports the oncologic safety of immediate oncoplastic surgery for diffusely growing tumors such as ILC, providing it an ideal option for patients desiring BCS.

Indexed as

Breast NeoplasmsCarcinoma, LobularMammaplastyMargins of ExcisionMastectomy, SegmentalAdultAgedAged, 80 and overFemaleFollow-Up StudiesHumansMiddle AgedNeoplasm InvasivenessNeoplasm Recurrence, LocalPrognosisRetrospective StudiesBreast Conserving SurgeryInvasive Lobular CarcinomaLumpectomyOncologic SafetyOncoplastic Reduction MammoplastyPositive MarginsRecurrence Free SurvivalSurgical Outcomes

Identifiers

PMID38713388
PMCPMC11452432

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.